These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15208819)

  • 1. Oxaliplatin: practical guidelines for administration.
    Sorich J; Taubes B; Wagner A; Hochster H
    Clin J Oncol Nurs; 2004 Jun; 8(3):251-6. PubMed ID: 15208819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
    Berg D
    Oncol Nurs Forum; 2003; 30(6):957-66. PubMed ID: 14603353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
    Kato K; Inaba Y; Tsuji Y; Esaki T; Yoshioka A; Mizunuma N; Mizuno T; Kusaba H; Fujii H; Muro K; Shimada Y; Shirao K
    Jpn J Clin Oncol; 2011 Jan; 41(1):63-8. PubMed ID: 20819832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
    Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
    J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
    Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersensitivity reactions to oxaliplatin: what nurses need to know.
    Bonosky K; Miller R
    Clin J Oncol Nurs; 2005 Jun; 9(3):325-30. PubMed ID: 15973843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Chang DZ; Abbruzzese JL
    Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
    [No Abstract]   [Full Text] [Related]  

  • 13. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives in the treatment of colorectal cancer.
    Ozer H; Diasio RB
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):14-8. PubMed ID: 15726534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
    Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H
    J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy in metastatic colorectal cancer.
    Christopoulou A
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s43-6. PubMed ID: 15655639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education.
    Moore S
    Cancer Nurs; 2007; 30(2):112-22; quiz 123-4. PubMed ID: 17413776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin: third-generation platinum analog.
    Wilkes G
    Clin J Oncol Nurs; 2003; 7(3):353-6. PubMed ID: 12793347
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors Influencing the Appearance of Oxaliplatin-Induced Allergy.
    Nishihara M; Nishikura K; Morikawa N; Yokoyama S
    Biol Pharm Bull; 2017; 40(12):2105-2109. PubMed ID: 29199235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.